GLCCI1基因在儿童激素抵抗性哮喘的研究进展

Research Progress of GLCCI1 Gene in Children with Hormone-Resistant Asthma

支气管哮喘是中国儿童常见的慢性肺部疾病,对于哮喘急性期的药物治疗主要是全身应用糖皮质激素(GC)、哮喘缓解期的药物主要是吸入性糖皮质激素(ICS),其中有一部分成人、儿童使用GC治疗后效果仍然不理想,这不利于哮喘儿童的治疗及预后。有越来越多的研究表明糖皮质激素诱导的转录本1 (GLCCI1)基因在哮喘发生及GC治疗中发挥重要作用。本文将在GLCCI1基因多态性在糖皮质激素抵抗性哮喘(SRA)的影响方面进行阐述。Bronchial asthma is a common chronic lung disease in Chinese children. For acute stage of asthma, systemic glucocorticoid (GC) is the main drug treatment, and for asthma remission stage, inhaled glucocorticoid (ICS) is the main drug treatment. Some adults and children still have unsatisfactory effects after GC treatment, which is not conducive to the treatment and prognosis of children with asthma. More and more studies have shown that glucocorticoid-induced transcript 1 (GLCCI1) gene plays an important role in asthma development and GC treatment. This article will discuss the effect of GLCCI1 gene polymorphism on glucocorticoid-resistant asthma (SRA).